[Nanofiltration in production of Beriplex P/N: increasing the capacity of virus elimination while maintaining product quality] NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Nanofiltration in production of Beriplex P/N: increasing the capacity of virus elimination while maintaining product quality]

Beitr Infusionsther Transfusionsmed. 1996;33:220-4. Unique Identifier : AIDSLINE MED/97019462
Romisch J; Groner A; Bernhardt D; Diehl KH; Hein B; List W; Muller HG; Nowak T; Ronneberger H; Schuler E; Weimer T; Hilfenhaus J; Centeon Pharma GmbH, Marburg/Lahn, Deutschland.

Abstract: For the manufacture of the PCC Beriplex P/N, nanofiltration was introduced into the production process of Beriplex HS providing an additional means to heat treatment for the clearance/inactivation of viruses. By nanofiltration, large enveloped viruses (HSV-1, HIV-1) were completely eliminated by a factor of more than 7 log10. While medium-sized enveloped viruses (HBV, BVDV) were cleared by a factor of approximately 4 log10, small non-enveloped viruses (poliovirus) were not removed. The product profile remained, no thrombogenic activities were detected.
Keywords: Blood Coagulation Factors/*THERAPEUTIC USE *Blood-Borne Pathogens Diarrhea Virus, Bovine Viral/ISOLATION & PURIF English Abstract Hepatitis B Virus/ISOLATION & PURIF Herpesvirus 1, Human/ISOLATION & PURIF Human HIV-1/ISOLATION & PURIF Polioviruses/ISOLATION & PURIF Viruses/*ISOLATION & PURIF JOURNAL ARTICLEKWDbloodcoagulationfactors/KWDtherapeuticuseKWDblood-bornepathogensdiarrheavirus,bovineviral/isolation&purifenglishabstracthepatitisbvirus/isolation&purifherpesvirus1,human/isolation&purifhumanhiv-1/isolation&purifpolioviruses/isolation&purifviruses/KWDisolation&purifjournalarticle
970228
M9721931

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .